Recombinant DNA Advisory Committee - 06/7-8/93 
Minoru Hirama, Viagene, Inc. 
Sharon Hoff, Department of Agriculture 
David Holzman, BioWorld 
Joseph Ilan, Case Western Reserve University 
John Jaugstetter, Genentech, Inc. 
Susan Jenks, Journal of the National Cancer Institute 
Joel Jessee, Life Technologies, Inc. 
William Johnston, Baxter Health Care 
Douglas Jolly, Viagene, Inc. 
George Kalf, Thomas Jefferson University 
Steve Kanzer, The Castle Group 
Kathy Kaufmann, Theragen, Inc. 
John Kavanagh, MD Anderson Cancer Research Center 
Donald Kohn, Childrens Hospital of Los Angeles 
Toshi Kotani, Genetic Therapy, Inc. 
Alex Kuta, Food and Drug Administration 
Donald Longnecker, Viagene, Inc. 
Richard Lundberg, Biogen, Inc. 
Daniel Maneval, Canji, Inc. 
Carol Marcus-Sekura, Food and Drug Administration 
Michael McCann, The Blue Sheet 
Gerard McGarrity, Genetic Therapy, Inc. 
Steven Mento, Viagene, Inc. 
Bruce Merchant, Viagene, Inc. 
Teri Merrill, Oncology News 
Noel Messenger, Applied Immune Sciences 
Fred Miller, Food and Drug Administration 
Robert Moen, Genetic Therapy, Inc. 
Richard Moscicki, Genzyme Corporation 
Annemarie Moseley, Applied Immune Sciences 
Gary Nabel, University of Michigan 
Philip Noguchi, Food and Drug Administration 
Terry O'Hanlon, Food and Drug Administration 
Sheryl Osborne, Viagene, Inc. 
Jeffrey Ostrove, Microbiological Associates, Inc. 
Enzo Paoletti, Virogenetics Corporation 
Stewart Parker, Targeted Genetics, Inc. 
Liz Pennisi, Science News 
Anne Petruska, The Blue Sheet 
Cary Pfeffer, Biogen, Inc. 
Stephen Pijar, University of Maryland 
Chris Platsoucas, Temple University 
Recombinant DNA Research, Volume 17 
[547] 
